SYMPOSIUM ANTIMICROBIAL RESISTANCE IN THE NEXT 10 YEARS: HUMANKIND, BUGS AND DRUGS Play video Chairs: F. Menichetti (Italy), G.M. Rossolini (Italy)
10.00 - 10.15	Global epidemiology of antimicrobial resistance in Gram-negatives - A. Brink (South Africa)
10.15 - 10.30	Global epidemiology of antimicrobial resistance in Gram-positives - S. Stefani (Italy)
10.30 - 10.45	Antimicrobial stewardship - M.V. Villegas (Colombia)
10.45 - 11.00	Diagnostic stewardship - S. Kanj (Lebanon)
11.00 - 11.15	General PK/PD rules for antibiotic use in critically ill patients - J. De Waele (Belgium)
11.15 - 11.45	Discussion
	SYMPOSIUM HOT TOPICS AMONG GRAM NEGATIVES WITHIN THE COVID ERA Video recording NOT available Chair: S. Kanj (Lebanon),
11.45 - 12.05	Changing epidemiology during COVID-19 - R. Canton (Spain)
12.05 - 12.25	Are PK/PD principals “baked in” to the newer regimens? - D. Nicolau (USA)
12.25 - 12.45	Discussion
	SYMPOSIUM GRAM-NEGATIVE INFECTIONS AND ADEQUATE TREATMENT Play video Chairs: T. Calandra (Switzerland), J.F. Timsit (France)
14.15 - 14.30	Risk stratification in empirical treatment - P. Montravers (France)
14.30 - 14.45	The importance of an early and appropriate empirical treatment in critically ill patients.  Practical algorithm - J.F. Timsit (France)
14.45 - 15.00	How to apply PK/PD rules in critically ill patients - F. Pea (Italy)
15.00 - 15.15	Role of new antimicrobials - D.P. Nicolau (Usa)
15.15 - 15.30	Role of old antibiotics - G. Dimopoulos (Greece)
11.50 - 12.00	Discussion
	SYMPOSIUM HOW TO MANAGE DIFFICULT TO TREAT BUGS? Play video Chairs: F.G. De Rosa (Italy), E. Bouza (Spain)
16.15 - 16.30	ESBL and AmpC - Y. Carmeli (Isreal)
16.30 - 16.45	KPC and OXA-48 - D.R. Giacobbe (Italy)
16.45 - 17.00	Pseudomonas aeruginosa - S. Kanj (Lebanon)
17.00 - 17.15	MBL - M. Falcone (Italy)
17.15 - 17.30	Acinetobacter baumannii - G. Poulakou (Greece)
17.30 - 17.45	MRSA - M. Wilcox (UK)
17.45 - 18.00	VRE - M. Mikulska (Italy)
18.00 - 18.15	Discussion

	SYMPOSIUM FUNGAL INFECTIONS IN CRITICALLY ILL PATIENTS AND HEMATOLOGICAL PATIENTS Play video Chairs: P. Munoz (Spain), C. Tascini (Italy)
09.00 - 09.15	Aspergillosis in COVID-19 and influenza - O. Cornely (Germany)
09.15 - 09.30	Invasive candidiasis - A. Vena (Italy)
09.30 - 09.45	Rare fungal infection - P. Munoz (Spain )
09.45 - 10.00	New antifungals - R. Kozlov (Russia)
10.00 - 10.20	Discussion
	SYMPOSIUM UPDATE AND PERSPECTIVES ON DIAGNOSIS, PATHOGENESIS, CLINICAL AND THERAPEUTIC ASPECTS OF COVID-19 Play video Chairs: M. Bassetti (Italy), T. Calandra (Switzerland),
10.50 - 11.05	Vaccine for COVID-19: actual and future perspectives - G. Rezza (Italy)
11.05 - 11.20	Progress in diagnosis of SARS-Cov 2 - M. Clementi (Italy)
11.20 - 11.35	Update on clinical aspects of COVID-19 - P.L. Viale (Italy)
11.35 - 11.50	Role of antivirals - M. Bassetti (Italy)
11.50 - 12.05	Role of corticosteroids and other antinflammatory agents - M. Kollef (Usa)
12.05 - 12.20	Role of antibiotics - J.F. Timsit (France)
12.20 - 12.35	Role of Monoclonal Antibodies - R. Burioni (Italy)
12.35 - 12.50	Covid and sepsis - T. Calandra (Switzerland)
12.50 - 13.15	Discussion
	LECTURE Play video Chair: O. Cornely (Germany)
14.15 - 14.45	Role of 5th generation cephalosporin in hospital - C. Tascini (Italy)
	SYMPOSIUM UPDATE ON ACTUAL AND NEW ANTIBIOTICS Play video Chairs: D. Nicolau (USA), A. Gori (Italy)
14.45 - 15.00	Ceftazime/avibactam - A. Soriano (Spain)
15.00 - 15.15	Ceftolozane/tazobactam - A. Shorr (USA)
15.15 - 15.30	Meropenem/Vaboarbactam - P. Montravers (Italy)
15.30 - 15.45	Cefiderocol - M. Bassetti (Italy)
15.45 - 16.00	Imipenem/relebactam M. Kollef (USA)
16.00 - 16.15	Other combinations S. Kanj (Lebanon)
16.15 - 16.35	Discussion
	SYMPOSIUM DIFFICULT AND COMPLICATED INFECTIONS Play video Chairs: P. Montravers (France), M. Venditti (Italy)
16.35 - 16.50	Abdominal infections - D. Eckmann (UK)
16.50 - 17.05	vHAP and VAP - J.F. Timsit (France)
17.05 - 17.20	Role of long acting glycopeptides in Gram-positive infections - E. Bouza (Spain)
17.20 - 17.35	Catheter - related infections - M. Tumbarello (Italy)
17.35 - 17.50	CDAD - M. Wilcox (UK)
17.50 - 18.10	Discussion